The study's objective was to determine effects of relative size and placement location of endoluminal stents on incidence of complications and survival for canine tracheal collapse. Measurements were obtained on lateral radiographs before and after stenting to determine percent of the trachea occupied by the stent. These values were monitored over time and compared to complication rates and survival. Overall median survival time was 502 days. Six month survival rate was 78%, 1 yr survival was 60%, and 2 yr survival was 26%. Median percent of trachea occupied by the stent at initial placement was 79% (range, 41-93%). Percent of the trachea occupied by the stent at the time of 
Introduction
Tracheal collapse is a respiratory condition that commonly affects small and toy breed dogs. With this condition, the integrity of the tracheal cartilage progressively weakens, there is laxity of the dorsal tracheal membrane that causes increased upper airway resistance, and this ultimately progresses to partial or complete airway obstruction. 1, 2 This can further be exacerbated by development of chronic tracheal and/or small airway inflammation, fibrosis, and the loss of the mucociliary apparatus. 1 History and clinical signs usually involve a characteristic ''goose honk'' cough that is often accompanied by intermittent or worsening episodes of respiratory difficulty. Commonly affected breeds include the Yorkshire terrier, Chihuahua, Pomeranian, miniature poodle, and pug, with no sex predilection reported. [3] [4] [5] [6] Diagnosis is made based on history and physical exam findings, followed by documenting the collapse with imaging. Severity of tracheal collapse is typically graded on a scale of I to IV, associated with 25, 50, 75, and 100% luminal collapse, respectively. 7, 8 Surgery for tracheal collapse is considered by some to be a last resort since medical management using a combination of antiinflammatories, antitussives, bronchodilators, antibiotics, and sedatives or tranquilizers can provide acceptable amelioration of signs for a protracted time period, and risks of surgical intervention are typically not benign. 3, [9] [10] [11] A 71% rate of resolution of clinical signs with medical management for greater than 12 mo in a survey of 100 cases has been reported. 8 Surgery for tracheal collapse may be indicated in cases that are no longer responsive to conservative management. Reported surgical techniques have included dorsal tracheal membrane plication, tracheal resection and anastomosis, and extraluminal prostheses. 3, 4, [9] [10] [11] Surgery, however, is of limited value in cases of significant intrathoracic tracheal collapse since associated surgical morbidity to treat intrathoracic tracheal disease is considered by some to be prohibitive. 1, 6, 12 Results of surgical treatment for tracheal collapse are variable and can precipitate serious and sometimes fatal complications, including laryngeal paralysis, tracheal necrosis, and pneumothorax. 2, 3, 11 Endoluminal tracheal stenting has become an important and promising alternative to conventional surgical techniques. This approach to treating tracheal collapse has the advantages of shortening anesthetic time, providing immediate relief of respiratory distress, and allowing minimally invasive access to the intrathoracic trachea. 5, 2, 13 Potential complications for this method include stent fracture, stent collapse or deformation, stent migration, stent shortening, tracheal perforation during placement, exuberant granulation tissue formation, bacterial or sterile tracheitis, pneumonia, and persistent coughing. 1, 6, [14] [15] [16] [17] It should be noted that persistent coughing, while partially a consequence of direct tracheal irritation by the stent, is also likely a result of progressive bronchial collapse, tracheitis, lower airway inflammation, and/or mucosal hyperplasia. Client education should emphasize that endoluminal stenting is intended to ameliorate the collapse and not, necessarily, the cough itself. 4, 5, 16 Factors contributing to survival, treatment success, and longterm outcome remain difficult to determine. Studies have demonstrated that 11-25% of patients with tracheal stents die within 6 mo of placement, with stent fracture being one of the most commonly reported serious complications, occurring in 22-41% of cases. 5, 18 Recently, it has been shown that 89% of stents will shorten in dimension over time, though this finding has not been found to correlate with outcome. 5 To date, no study has identified specific factors associated with a better or worse long-term outcome and survival with endoluminal stenting.
Some studies describe an aim to support as much of the working length of the trachea as possible with the stent without impinging on the larynx and carina. 5, 16 The optimal location of the stent within the trachea, however, has not yet been determined. The purpose of this study was to evaluate cases of tracheal collapse treated with endoluminal stenting. We specifically determined the percent of tracheal length occupied by the stent, the distance from the stent to the larynx and carina, respectively, and the changes in stent length over time. These values were then compared to complications and survival time. The hypothesis of the study herein was that a larger initial percent coverage of the trachea by the stent would correlate to improved survival. Additionally, it was hypothesized that cases in which the stent shortened over time would have a shorter survival time.
Materials and Methods
Medical This was typically at the level of the fourth intercostal space, at which point stent deployment was initiated. As the stent was deployed within the trachea, the patient was simultaneously slowly extubated until the stent was fully deployed or it was determined that a different stent length was required. If the stent size was deemed inappropriate, the stent was recaptured and a different size was selected and placed. If clinical judgment deemed stent size selection to be adequate, the stent was deployed completely, and the empty delivery system was retracted as the patient was simultaneously completely extubated. Because the inhalant anesthetic was not administered during stent delivery through the Tport, propofol was administered intravenously when necessary, titrated to effect. The patient was not reintubated as to prevent dislodgement of the stent, and was allowed to fully recover from anesthesia under close monitoring. Ventrodorsal and lateral cervicothoracic radiographs were taken in all cases for confirmation and documentation of appropriate stent placement
Postplacement Care
Following radiography the patients were monitored during recovery from anesthesia. Patients were treated with 0.5-1 mg/kg of prednisolone acetate subcutaneously, and respiratory rate and effort were recorded hourly peri-operatively. Patients remained on a maintenance fluid rate of physiologic isotonic crystalloids, and broad spectrum oral antibiotics were initiated upon full recovery from anesthesia. Excitement or anxiety with associated respiratory distress was treated with butorphanol at 0.2 mg/kg IV, as indicated.
In the absence of postoperative complications, most patients were discharged on amoxicillin/clavulinic acid (twice daily for 6 wk),
and an anti-inflammatory dose of prednisone (0.25-0.5 mg/kg twice daily) for 6 wk, with instructions to taper thereafter over 3
wk. Cough suppressants (hydrocodone/homatropine, butorphanol, diphenoxylate/atropine) were also used as needed.
Tracheal and Stent Dimensions
Measurements were taken retrospectively to assess tracheal dimensions both before and after stenting. Preoperative tracheal measurements were taken from the radiographs obtained closest to the time of stenting, typically on the same day of the procedure. Radiographs obtained immediately following tracheal stent placement were used to determine stent position and percent of the trachea covered.
When possible, tracheal and stent dimensions were followed over time and recorded. Measurements were obtained using the electronic measurement tools provided by the radiograph viewing software used. All measurements were taken in triplicate by a single observer (S.R.), using the mean for data analysis. These values were then converted to a percentage of total tracheal length.
Prestent tracheal length measurements were obtained from the caudal-most aspect of the cricoid cartilage to the level of the tracheal bifurcation. In most cases, due to the curvilinear orientation of the trachea, a single measurement was taken from the cricoid to the level of the thoracic inlet, and an additional measurement was taken from the inlet to the carina, and these measurements were added to generate a tracheal length.
Poststent placement measurements were obtained on the lateral projection from the caudal aspect of the cricoid cartilage to the cranial aspect of the stent, and from the caudal aspect of the stent to the level of the tracheal bifurcation. These measurements determined distances from the stent to the larynx and the carina, respectively. In order to control for magnification, these values were then subtracted from the total tracheal length, and the result expressed as a percentage representing the proportion of the trachea supported by the stent. An example of a lateral post-stent radiograph with annotated measurements can be found in Figure 1 .
When available, follow-up radiographs were used to obtain the same measurements. The percent of tracheal coverage at initial placement was compared to the percent tracheal coverage at follow-up visits; change in stent length was determined and expressed as a percentage. If more than one radiographic study was available from follow-up visits, then the most recent radiographs obtained were used to compare to those taken after initial stent placement. All radiographs included in data analysis contained a marker in the projection for purposes of magnification calibration.
Follow Up
Initial recheck examinations were performed 2 wk after initial stent placement and again at 6 wk to adjust medications if indicated.
Thereafter, appointments were recommended every 6 mo.
Data Collection
Several variables were examined to determine how the percent of trachea covered by the stent affected outcome. Patients were categorized according to their cause of death; specifically, whether or not death was directly due to respiratory disease. Specific inquiries included initial percent tracheal coverage, changes in stent dimension over time, as well as distances from the cranial and caudal aspects of the stent to the larynx and carina, respectively.
These variables were then analyzed in relation to incidence of complications as well as overall survival time. Initial percent tracheal coverage was also examined as a potential risk factor for death due to respiratory disease. did not meet the inclusion criteria, and twenty-seven patients were included in this study. The most common breed represented was Median survival time for all 27 patients was 502 days (range 3 to 1558 days). Five patients (18.5%) died within the first mo after stent placement. Median survival for patients who lived beyond 1 mo was 535 days. These survival time differences were not statistically significant. Twenty-one out of 27 patients (78%) survived at least 6 mo, 16/27 patients (60%) survived .1 yr, and 7/27 patients (26%)
Statistical Analysis
lived .2 yr. Figure 2 depicts overall survival time.
Thirteen out of 27 patients (48%) ultimately died due to respiratory disease, 6/27 (22%) patients died of unrelated causes, 2/ 27 (7%) patients died due to unknown causes, 5/27 (19%) patients were still alive at the time of study completion, and 1 patient was lost to follow-up (4%).
Serious complications were defined as any complication directly related to the stent that resulted in hospitalization, a second procedure, or death. These included granuloma formation (5/27), pneumonia (4/27), stent deformation (1/27), stent fracture
(1/27), and stent migration (1/27). Serious complications occurred in 10 patients (37%), and 2 of these patients experienced more than one complication. days. There was no statistical significance between groups (P ¼ .310).
Multivariate Tests
Multivariate tests were used primarily to test for possible confounding because only one variable was significant in the univariate tests at the P ¼ .05 level, and all other variables were not significant even at the .3 level. Tests of all, as well as all pairs of variables, indicated no confounding was present. This analysis also confirmed the univariate analysis: only the occurrence of a serious complication had a statistically significant ability to predict survival time (P ¼ .039).
Complications
Complications associated with the stent placement procedure itself were recorded in only one dog. In this case, the stent was found to cause laryngeal impingement after complete deployment. Subsequently, the stent was withdrawn orally using hemostats without incident, and a shorter stent was placed. On fluoroscopic and radiographic assessment, the second stent had ideal placement. In another dog, the placement procedure was uneventful, and fluoroscopy confirmed appropriate stent placement. However, the following morning, radiographs obtained revealed stent migration into the mainstem bronchus, and the patient was re-anesthetized for stent repositioning. The stent was accessed orally using a small wire hook and was retracted cranially to its correct position. A lateral cervicothoracic radiograph obtained after the procedure confirmed appropriate stent positioning, and stent migration was not a recurrent problem during the patient's 7 mo survival period.
Two patients exhibited stent-related complications that did not result in specific treatment. One patient developed a clinically silent pneumothorax after stent placement that self-resolved. For all patients who developed a granuloma cranial to the stent, the average time to granuloma formation after initial stent placement was 9.5 mo (range 69-561 days). For patients who received a second stent (four patients), average survival following additional stent placement was 13.3 mo.
Material failure was another source of stent-related complications. One patient experienced stent fracture 26 days after placement and was euthanized the following day. Another patient presented 15 days after initial stent placement for respiratory distress. Stent deformation was noted on radiography, and this patient was anesthetized for ballooning of this segment, as was offered in a previous case report of material fracture. 15 Under the same anesthetic event, an extraluminal prosthetic tracheal ring was surgically placed in this region for added support. The patient recovered from anesthesia well, and was discharged from the hospital 2 days later. This patient died suddenly at home 2 days after that, with causes presumably attributable to complications.
The remaining four serious complications comprised cases of pneumonia, all diagnosed via radiography. One patient developed aspiration pneumonia in the first few hours after stent placement, ultimately dying before being discharged from the hospital.
Another patient developed pneumonia that was documented radiographically immediately poststent placement. This patient responded well to supportive care and empiric antibiotic therapy and was discharged from the hospital 3 days later. The remaining two patients developed pneumonia 8 days and 2 years after stent placement, respectively, and both responded to empiric antibiotic therapy.
Discussion
The purpose of this paper was to examine cases of tracheal stent placement and to determine whether the amount of trachea supported by the stent makes a difference in long-term outcome. It was hypothesized that patients who had larger percentages of their trachea supported by a stent would live longer and be less likely to experience complications than patients who had less of their trachea supported, leaving larger portions subject to collapse.
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Additionally, we wanted to investigate the incidence of changes in stent diameter over time and determine if this phenomenon affected outcome.
Overall median survival for our patients was 502 days, with 78% of patients surviving at least 6 mo, 60% of patients surviving at least 1 yr, and 26% of patients surviving at least 2 yr. This is comparable to previous reports, in which one study showed a 25% mortality rate within the first 6 mo, and another showed an 11% mortality rate within the first 60 days. 18, 5 Compared with surgical treatment for tracheal collapse using extraluminal prostheses alone, wherein long-term survival ranges have reportedly been between 70-85%, our results show similar longevity, with 60-78% living 6 mo to a yr or more. 9, 10 Most recently, one study on long-term outcome for patients with extraluminal ring placement showed a median survival of 50.5 mo for patients treated for their cervical tracheal collapse. While this is a definitively favorable outcome, it should be noted that 17% of these cases overall developed laryngeal paralysis postoperatively.
11
In looking at factors that might affect survival time, none of the variables examined exhibited a statistically significant correlation to a shorter survival. However, patients exhibiting serious complications did have a shorter median survival time at 208 days, as compared to 543 days for those who did not experience complications, with a P value approaching significance at .072, suggesting that survival times may not be as favorable in these cases. Explanation for this finding is likely related to the nature of serious complications, as they are defined as those resulting in hospitalization, a second procedure, or death. Because these complications require in-patient therapy to which patients are sometimes refractory, it is not surprising that survival time may not be as favorable in these cases.
Percent of the trachea that the stent occupied at initial placement was not found to significantly affect survival; that is to say, a longer percent tracheal coverage did not correlate to a longer survival as we had expected. In addition, those who experienced serious complications did not have a significantly different percent tracheal coverage than those who did not experience complications.
This was interesting to note, as we expected that a larger proportion In measuring the percent of the trachea covered by the stent, measurements were taken of the trachea prior to stent placement on a lateral radiographic projection to evaluate the overall length. A recent study showed no significant difference between computed tomography and radiographic measurements regarding tracheal length on lateral projections, making radiography an appropriate method to assess this parameter. 21 Previous reports highlight stent fracture as the most frequent complication associated with tracheal stenting, occurring in 42% of patients in one study and 22% of dogs in another report. 5, 18 This is in contrast to our findings, in which stent fracture occurred in 1/27 (4%) patients. Reasons for this difference are unclear though may be related to the frequency of coughing or differences in relative stent motion.
The most frequent serious complication encountered in this population of patients was granuloma formation at the cranial aspect of the stent, documented to have occurred in 18.5% of our cases. Interestingly, all of the cases treated for this complication had manifestations at the cranial aspect of the stent, visible either radiographically or via tracheoscopy. Etiology for the formation of excessive granulation tissue adjacent to the stent has not been specifically defined. In humans, it is thought to occur in patients with pre-existing tracheal inflammation at the time of stent placement. 22 One study showed an incidence of bacterial tracheitis in 42% of dogs after tracheal stent placement. 5 It is possible that granuloma formation may be either a result or a cause of bacterial tracheitis, and it is the authors' opinion that antibiotic use should be strongly considered for these cases. In the same study, another 42% of dogs were diagnosed with inflammatory tracheitis after stent placement, as confirmed via cytologic analysis paired with a negative bacterial culture. 5 Causes for this inflammatory tracheitis may include direct irritation of the trachea by the stent, small movements of the stent interstices during coughing, or tracheal irritation from continued bronchial collapse with associated coughing. 5 Presence of pre-existing tracheitis may predispose to granuloma formation in dogs, which can further impair expulsion of respiratory secretions as well as causing direct airway obstruction and respiratory distress. In the absence of tracheitis, it is possible that mechanical irritation from small movements of the stent during coughing or other changes in tracheal dimensions could incite a focal deposition of granulation tissue. Medical treatment of a stent-related granuloma resulting in resolution has been documented in a dog using colchicine therapy. 22 However, treatment with oral doxycycline was instituted concurrently in that case report, making it difficult to attribute resolution of the granuloma to the colchicine therapy alone. Colchicine therapy was instituted in two of our patients with documented granulomas, and no clinical improvement was noted.
For four of our patients that developed a granuloma, an additional stent was placed with the intent to cover the area of granulation tissue, aiming to increase lumen diameter and decrease airway resistance. To the author's knowledge, this treatment has not been specifically described to address granuloma formation.
While the sample of patients with this treatment was small, our impression is that this technique results in a significant extension in 
